[C:1]([N:8]1[CH2:13][CH2:12][CH:11](CBr)[CH2:10][CH2:9]1)([O:3][C:4]([CH3:7])([CH3:6])[CH3:5])=[O:2].[H-].[Na+].C(OC([C:24]1[CH:25](C2C=CC=C(Cl)C=2)[N:26]=[C:27](OC)[NH:28][C:29]=1C)=O)(C)C.N1CCCCC1.N1C=CC=NC1>[I-].C([N+](CCCC)(CCCC)CCCC)CCC.CN(C)C=O>[NH:28]1[CH:29]=[CH:24][CH:25]=[N:26][CH2:27]1.[C:1]([N:8]1[CH2:9][CH2:10][CH2:11][CH2:12][CH2:13]1)([O:3][C:4]([CH3:7])([CH3:6])[CH3:5])=[O:2]Tetrabutyl ammonium iodide (0.39 mmol) was added to a solution of N-Boc 4-bromomethyl piperidine (0.58 mmol; prepared as described in Bioorganic and Medicinal Chemistry Letters, 9, 2615, (1999)) in dimethylformamide (1 ml) at ambient temperature for 20 minutes. In a second vessel, NaH (0.47 mmol) was added to a solution of 2-methoxy-6-methyl-4-(3-chloro-phenyl)-1,4-dihydro-pyrimidine-5-carboxylic acid isopropyl ester (0.39 mmol) in dimethylformamide (1 ml) at ambient temperature and stirred for 20 minutes. The piperidine solution was then added to the dihydropyrimidine solution and stirred for approximately 2 hours. The reaction was quenched by addition of water, diluted with ethyl acetate, and subsequently washed with water and brine solution. The acetate layer was dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting material was purified via silica gel chromatography utilizing 20% ethyl acetate/hexanes eluent affording the corresponding N Boc piperidine dihydropyrimidine intermediate 195A in 29% yield.